Rituximab Therapy for Primary Sjogren's Syndrome: An Open-Label Clinical Trial and Mechanistic Analysis

Department of Medicine, Duke University Medical Center, Durham, NC. .
Arthritis & Rheumatology (Impact Factor: 7.87). 04/2013; 65(4). DOI: 10.1002/art.37850
Source: PubMed

ABSTRACT OBJECTIVE.: To study the safety and clinical efficacy of rituximab therapy for primary Sjögren's syndrome, as well as investigate its mechanisms. METHODS.: Patients with primary Sjögren's syndrome were enrolled in an open-label trial and received rituximab (1 g) on days 1 and 15 and followed through week 52. The primary endpoint was safety, with secondary endpoints evaluating clinical and biologic efficacy. Blood was obtained for enumeration of lymphocyte subsets, measurement of serum autoantibodies and BAFF levels, and analysis of gene expression. RESULTS.: Twelve female subjects with primary Sjögren's syndrome were administered rituximab. They had a median (range) age of 51 (34-69) years and a median (range) disease duration of 8.0 (2-18) years. We observed no unexpected toxicities from rituximab therapy. Modest improvements were observed at week 26 in patient-reported symptoms of fatigue and oral dryness, with no significant improvement in the objective measures of lacrimal and salivary gland function. The recovery of blood B cells following the nadir from rituximab therapy was characterized by a predominance of transitional B cells and a lack of memory B cells. While blood B cell depletion was associated with an increase in serum BAFF levels, no significant changes were observed in the levels of serum anti-Ro/SSA, anti-La/SSB, and anti-muscarinic receptor 3 autoantibodies or in the blood IFN signature. CONCLUSION.: In primary Sjögren's syndrome, a single treatment course of rituximab was not associated with any unexpected toxicities and led to only modest clinical benefits despite effective depletion of blood B cells.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Primary Sjögren's syndrome (pSS) is an autoimmune disorder affecting exocrine glands and characterized in most cases by a rather mild clinical picture. However, a subgroup of pSS patients experience systemic extraglandular involvement leading to a worsening of disease prognosis. Current therapeutic options for the treatment of pSS are mainly empirical, often translated by other autoimmune diseases, and recent systematic reviews have highlighted the lack of evidence-based recommendations for most of the drugs commonly employed in the spectrum of extraglandular involvement. Because of the well-established role of B-lymphocytes in the pathogenesis of pSS, a B-cell targeting therapy may represent a new and intriguing therapeutic approach; in this context, growing evidence suggests that B-cell depletion by rituximab (RTX) is also effective in pSS. Of interest, besides clinical efficacy, RTX also showed biologic effects, consistently affecting the inflammation and the lymphoid organization that occur in target tissue. Moreover, the good results observed in the published trials after RTX treatment in pSS should represent the starting point to develop evidence-based guidelines for the use of biologic therapy in this disease.
    Lupus 08/2014; 23(13). DOI:10.1177/0961203314546023 · 2.48 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: This article discusses the specific neurologic issues that arise in patients with rheumatic diseases such as rheumatoid arthritis, systemic lupus erythematosus, and Sjo¨gren syndrome. Diagnosis and management are discussed.
    CONTINUUM Lifelong Learning in Neurology 06/2014; 20(3, Neurology of Systemic Disease):657-669. DOI:10.1212/01.CON.0000450972.06947.37
  • [Show abstract] [Hide abstract]
    ABSTRACT: Primary Sjögren syndrome is a systemic autoimmune disease whose clinical spectrum extends from sicca syndrome to systemic involvement (extraglandular manifestations). Recent reports have focused on expanding the clinical characterization and improving the diagnostic and therapeutic management of systemic Sjögren.
    Current Opinion in Rheumatology 07/2014; DOI:10.1097/BOR.0000000000000096 · 5.07 Impact Factor